Mrs Linda June Melvin, LMFT | |
216 E 2nd Ave, Big Timber, MT 59011-7855 | |
(406) 600-2454 | |
Not Available |
Full Name | Mrs Linda June Melvin |
---|---|
Gender | Female |
Speciality | Marriage & Family Therapist |
Location | 216 E 2nd Ave, Big Timber, Montana |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1780281022 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | 202714 (Texas) | Secondary |
106H00000X | Marriage & Family Therapist | 37565 (Montana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Linda June Melvin, LMFT Po Box 989, Big Timber, MT 59011-0989 Ph: (406) 600-2454 | Mrs Linda June Melvin, LMFT 216 E 2nd Ave, Big Timber, MT 59011-7855 Ph: (406) 600-2454 |
News Archive
A new technique developed by researchers at the Stanford University School of Medicine allows researchers to identify the exact DNA sequences and locations bound by regulatory RNAs. This information is necessary to understand how the recently identified RNA molecules control the expression of neighboring and distant genes.
For the first time ever, clinicians have the flexibility to track X-ray skin dose exposure in real time during interventional procedures with Toshiba America Medical Systems, Inc.'s Dose Tracking System. FDA cleared on Toshiba's InfinixTM-i cardiovascular X-ray systems for use in pediatric and adult cardiac and abdominal procedures, the new technology is Toshiba's latest advancement in optimizing dose management to improve patient safety.
Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection.
Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC.
Results of two clinical studies have added to evidence that blood-based liquid biopsies can accurately track lung cancer treatment responses by measuring circulating tumor DNA (ctDNA) during immunotherapy and related treatments.
› Verified 1 days ago